<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02610595</url>
  </required_header>
  <id_info>
    <org_study_id>ZY3-CCCX-3-2001</org_study_id>
    <nct_id>NCT02610595</nct_id>
  </id_info>
  <brief_title>Study on the Therapeutic Effect of TCM Treatment for MDR MN</brief_title>
  <official_title>A Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Putuo District Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ShuGuang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Yueyang Integrated Medicine Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Minhang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Traditional Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness and safety of the Chinese medicine treatment for multiple drug
      resistance of MN patients with Jianpiyiqi and Huoxuejiedu Recipe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on previous research, the investigators hoping to identity the standard treatment
      program for MDR IMN patients with high treatment difficulty, TCM syndrome of s Pixushuifan.
      Subsequently, to evaluate the effectiveness and safety of the Chinese medicine treatment for
      multiple drug resistance of MN patients with Jianpiyiqi and Huoxuejiedu Recipe. With twenty
      national-grade III hospital of to formed TCM Comprehensive treatment plan and to evaluate the
      effectiveness and safety of the Chinese medicine treatment for multiple drug resistance of MN
      patients with Jianpiyiqi and Huoxuejiedu Recipe. Furthermore, search for potential diagnostic
      predictor in IMN by Proteomics and Metabolomics. The investigators purpose is improve the
      clinical remission rate of MN, further establish the treatment of TCM in the treatment of MN.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate of 24 hours urinary protein quantitative</measure>
    <time_frame>two weeks to three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function, glomerular filtration rate (EPI formula), Plasma albumin</measure>
    <time_frame>two weeks to three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipid</measure>
    <time_frame>half a year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of TCM Syndrome</measure>
    <time_frame>two weeks to three months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jianpixiaozhong particles and Wuse Dietotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jianpixiaozhong particles and Wuse Dietotherapy</intervention_name>
    <description>Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years;

          2. Gender, nationality;

          3. Pixushuifan syndrome, IMN confirmed by renal biopsy and clinical examination;

          4. Treatment invalided by two or more than two kinds of Hormone or immunosuppressive
             agents ;

          5. CKD phase 1-3（eGFR（EPI Formula）≥30ml/min/1.73m2）

        Exclusion Criteria:

          1. Progressive MN (progressive renal impairment, renal biopsy confirmed Necrotic
             Vasculitis and Large crescent formation&gt;50%), combined with IgA nephropathy, diabetic
             nephropathy and other renal diseases;

          2. Anti-nuclear antibodies, double stranded DNA, ANCA or other indicators of immune
             disorders;

          3. Active hepatitis B and liver function test sustained abnormal;

          4. Patients with malignant tumor or have a history of cancer, HIV infection, history of
             mental illness, acute central nervous system diseases, severe gastrointestinal
             diseases;

          5. Merger with other serious disease and dysfunction of the organ;

          6. Gravid or lactation woman;

          7. Other clinical trials are being studied.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yueyi Deng, MD.</last_name>
    <phone>+86-021-64385700-3226</phone>
    <email>dengyueyi@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wanjia Chen, MS.</last_name>
    <phone>+86-021-64385700-3222</phone>
    <email>wdgzkj@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nephrology,Longhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>YueYI Deng, Dr.</last_name>
      <phone>64385700</phone>
      <phone_ext>3222</phone_ext>
      <email>lhkidney@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Membranous Nephropathy</keyword>
  <keyword>Jianpiyiqi Recipe</keyword>
  <keyword>Huoxuejiedu Recipe</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

